why natural?

Psychedelics were discovered in nature.

trees in a sunlit wooded forest

At Filament, we believe that nature – not a lab – is the best source for psychedelic drug candidates. There are hundreds of clinically unexplored psychedelic species, each containing multiple active compounds.

The mental health crisis is growing. In order to address it quickly, we believe in using compounds that are already known, rather than synthesizing new molecules which could take years to prove effective.

We have developed technology which creates drug candidates from natural psychedelic sources. Leveraging nature's historical evidence provides a faster path to human clinical trials.

Filament’s drug development pathway is the best of both worlds - we combine the benefits of well-known substances with robust IP protection. Our platform offers the potential for hundreds of drugs to be discovered and run through our in-house development program or through our partnership network.

What is a botanical drug?

Botanical drugs are derived from plant or fungal sources and contain multiple active compounds. Conversely, in synthetic drugs or drugs with an isolated natural compound, only the primary metabolite is present.

Picking Psilocybin mushrooms in the Filament lab

Botanical drugs are complex mixtures of different compounds. All the elements of their production affect the final composition of the drug. This includes the species and strains used, the growing and harvesting conditions, and the manufacturing methods. These are protected through patents or as trade secrets.

drug candidates

We have created the world’s first botanical psychedelic drug candidates:

PEX
PEX010
Oral capsule standardized to deliver 25 or 1 mg Psilocybin
PEX020
Oral capsule to deliver a standardized dose of Psilocin  (dose withheld)
PEX030
Sublingual tablet to deliver a standardized dose of Psilocin (dose withheld)
AEX
AEX010
Standardized ayahuasca formulation (dose withheld)
AEX020
Standardized monoamine oxidase inhibitor
Every drug candidate is covered by three distinct layers of IP protection:

✓ IP Trade Secrets / Complex Botanical Mixture
✓ Manufacturing Methods
✓ Compositions of Matter

Psilocin for the First Time

Psilocybin is a well-known compound found in magic mushrooms.

It is not bioactive in humans; it must convert into psilocin in order to cause hallucinogenic and therapeutic effects.

Bypassing this conversion by directly administering psilocin could mean faster onset time, fewer side effects, and more consistent dosing, but to date, it has never been done.

This is because psilocin is unstable, particularly when manufactured synthetically. To overcome this instability researchers have historically produced synthetic psilocybin, which is more stable.

Graph displaying plasma psilocin concentration levels that accompanies the administration of psilocybin.

Psilocin and intensity rating time course. A Plasma psilocin levels. Individual data points are measured plasma psilocin concentrations, fitted with spline fits. b Time course of subjective intensity ratings. Time = 0 indicates time of psilocybin ingestion

PMC full text:
Neuropsychopharmacology. 2019 Jun; 44(7): 1328–1334.        
© American College of Neuropsychopharmacology 2019

This data demonstrates the patient to patient variability in plasma psilocin levels that accompanies the administration of psilocybin. For the first time, our standardized psilocin will be directly administered in an effort to achieve more consistent dosing

By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.